• Our focus
    • Back
    • Our focus
    • Community engagement
    • Understanding brain diseases
      • Migraine awareness
      • Mental health awareness
    • Neurology
      • Alzheimer's Disease
      • Lennox-Gastaut Syndrome
      • Migraine
      • Parkinson's Disease
    • Psychiatry
      • Alcohol Use Disorder
      • Bipolar Disorder
      • Borderline Personality Disorder
      • Depression
      • Generalized Anxiety Disorder
      • Post-Traumatic Stress Disorder
      • Schizophrenia
    • Report a side effect
  • Our science
    • Back
    • Our science
    • Research and development
      • Our value chain
    • Products
    • Pipeline
    • Medical education
      • Lundbeck Institute
    • Clinical trials
      • Clinical trial diversity
      • Study synopses
    • Clinical data sharing
    • Publications
  • Stories
  • Sustainability
    • Back
    • Sustainability
    • ESG Commitments and principles
    • Access to brain health
    • Climate action
    • Donations and grants
    • Health and safety at work
    • Materials use and waste
    • Responsible business conduct
      • Code of Ethics
    • Suppliers and third-parties
    • Transparent interactions
  • About us
    • Back
    • About us
    • Our commitment
      • Inclusion, diversity & equity
      • Our position on Brain Health
      • Our position on Patient Centricity
    • This is Lundbeck
      • At a glance
      • Organization and ownership
      • The Lundbeck Foundation
      • Our history
    • Our leadership
      • Executive Leadership Team
      • Board of Directors
    • Corporate governance
      • Board tasks
      • Remuneration
      • Risk management
  • Code of Ethics
  • Careers
    • Back
    • Careers
    • Life at Lundbeck
      • Our culture and people
      • Building community
      • Employee development
    • Your job
      • Job opportunities
      • Career areas
      • Recruitment process
      • Unsolicited applications
    • Early career programs
      • Students
  • Investors
    • Back
    • Investors
    • Releases
      • Release subscription
    • Financials
    • Reports and presentations
      • Annual Reporting 2025
    • Events
      • Financial calendar and events
      • General meeting
    • Investor Portal
    • The share
      • Share data
      • Shareholders and dividends
      • Analyst coverage
      • New share structure
    • Debt
  • Partnering
    • Back
    • Partnering
    • Partnership initiatives
      • External Research & Innovation
      • Lighthouse Life Science
      • Lundbeck Biotech Incubator
      • HEAD-WINd®
    • Lundbeck CDM
  • Press
  • Contact
  • Other sites (Global)
    • Back
    • Global
      • Back
      • Global site
    • Americas
      • Back
      • Argentina
      • Brazil
      • Canada
      • Chile
      • Colombia
      • Mexico
      • Panama
      • Peru
      • United States
    • Asia
      • Back
      • China
      • Israel
      • Japan
      • Korea
      • Singapore
      • Turkey
    • Europe
      • Back
      • Austria
      • Belgium
      • Bulgaria
      • Czech Republic
      • Denmark
      • Estonia
      • Finland
      • France
      • Germany
      • Greece
      • Ireland
      • Italy
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Slovenia
      • Spain
      • Sweden
      • Switzerland
      • United Kingdom
    • Oceania
      • Back
      • Australia and New Zealand
    • Other Sites
      • Back
      • Drughunters
      • Elaiapharm
      • Lundbeck CDM
      • Lundbeck GBS Krakow
      • Brain Battle
      • Longboard Pharmaceuticals
  1. Home
  • Linkedin
  • Facebook
  • Email
  • Linkedin
  • Facebook
  • Email

Search Results

Dr. Johan Luthman appointed EVP and Head of Research & Development in Lundbeck
Dr. Johan Luthman appointed EVP and Head of Research & Development in Lundbeck
Dr. Johan Luthman udnævnt koncerndirektør for forskning og udvikling hos Lundbeck
Dr. Johan Luthman udnævnt koncerndirektør for forskning og udvikling hos Lundbeck
Lundbeck joins EHDEN
research programme currently in planning.”    Johan Luthman, Executive Vice President, Research & Development, Lundbeck, said, “Joining ...
Lundbeck_AGM_2024_presentation.pdf
Download
pdf, 3 MB
20241105_Lundbeck announces positive results from phase III pivotal trial (SUNRISE) of Vyepti® (eptinezumab) in migrain_J
Download
pdf, 611 KB
AGM_Presentation_2025_03_26.pdf
Download
pdf, 4 MB
20251205_ルンドベック、米国てんかん学会(AES)年次総会にて、希少な小児発症てんかん患者を対象とした新たなbexicaserinデータセットを発表
Download
pdf, 582 KB
20260217_ルンドベック、片頭痛予防を対象としたbocunebart(Lu AG09222;抗PACAP モノクローナル抗 体)の第IIb 相試験トップラインにおいて良好な結果を発表
Download
pdf, 802 KB
AGM Presentation 2026.pdf
Download
pdf, 3 MB
ルンドベックが開発中のLu AG13909、日本における先天性副腎過形成症およびクッシング病に対する希少疾病用医薬品指定を取得
Download
pdf, 648 KB
Annual report 2019.pdf
Download
pdf, 2 MB
annual-report-2019.pdf
Download
pdf, 2 MB
Lundbeck Annual Report 2019.pdf
Download
pdf, 2 MB
Previous 1 2 3 4 5 6 7 8 9 10 11 Next
Johan Luthman. Executive Vice President, R&D
Johan Luthman. Executive Vice President, R&D
Download
jpg, 1 MB
Johan Luthman, Executive Vice President, R&D
Johan Luthman, Executive Vice President, R&D
Download
jpg, 22 MB
Johan Luthman, Executive Vice President, R&D
Johan Luthman, Executive Vice President, R&D
Download
jpg, 22 MB
Johan Luthman, Executive Vice President, R&D
Johan Luthman, Executive Vice President, R&D
Download
jpg, 26 MB
Johan Luthman, Executive Vice President, R&D
Johan Luthman, Executive Vice President, R&D
Download
jpg, 18 MB
Johan Luthman, Executive Vice President, R&D
Johan Luthman, Executive Vice President, R&D
Download
jpg, 16 MB
Johan Luthman, Executive Vice President, R&D
Johan Luthman, Executive Vice President, R&D
Download
jpg, 17 MB
Johan Luthman.png
Johan Luthman.png
Download
png, 1 MB
Johan-Luthman.jpg
Johan-Luthman.jpg
Download
jpg, 1 MB
Johan_Luthman.jpg
Johan_Luthman.jpg
Download
jpg, 148 KB
1 2 Next

H. Lundbeck A/S

Ottiliavej 9
2500 Valby
Denmark

Headquarters

  • +45 3630 1311
  • info@lundbeck.com

Links

  • Report a side effect
  • Compliance hotline
  • Terms of use
  • Contact us
  • Social media principles
  • Cookie settings

Connect with us

Privacy policy

Copyright© 2026 H. Lundbeck A/S